JP2025519475A - Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用 - Google Patents

Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用 Download PDF

Info

Publication number
JP2025519475A
JP2025519475A JP2024572034A JP2024572034A JP2025519475A JP 2025519475 A JP2025519475 A JP 2025519475A JP 2024572034 A JP2024572034 A JP 2024572034A JP 2024572034 A JP2024572034 A JP 2024572034A JP 2025519475 A JP2025519475 A JP 2025519475A
Authority
JP
Japan
Prior art keywords
tcr
seq
cells
amino acid
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024572034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025519475A5 (enExample
Inventor
プロツァー，ウルリケ
ヴィスキルヒェン，カリン
ファン，イエンジョウ
ジン，タオ
ジャン，ケ
Original Assignee
エスシージー セル セラピー プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスシージー セル セラピー プライベート リミテッド filed Critical エスシージー セル セラピー プライベート リミテッド
Publication of JP2025519475A publication Critical patent/JP2025519475A/ja
Publication of JP2025519475A5 publication Critical patent/JP2025519475A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024572034A 2022-06-05 2022-12-08 Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用 Pending JP2025519475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210626787.7 2022-06-05
CN202210626787.7A CN117209588A (zh) 2022-06-05 2022-06-05 乙肝表面抗原特异性t细胞受体及其用途
PCT/SG2022/050892 WO2023239290A1 (en) 2022-06-05 2022-12-08 Hbv surface antigen specific t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025519475A true JP2025519475A (ja) 2025-06-26
JP2025519475A5 JP2025519475A5 (enExample) 2025-12-11

Family

ID=89039487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024572034A Pending JP2025519475A (ja) 2022-06-05 2022-12-08 Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用

Country Status (9)

Country Link
US (1) US20260021140A1 (enExample)
EP (1) EP4536695A1 (enExample)
JP (1) JP2025519475A (enExample)
KR (1) KR20250031233A (enExample)
CN (1) CN117209588A (enExample)
AU (1) AU2022462612A1 (enExample)
CA (1) CA3258313A1 (enExample)
IL (1) IL317429A (enExample)
WO (1) WO2023239290A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189281A1 (en) * 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Also Published As

Publication number Publication date
AU2022462612A1 (en) 2025-01-16
CA3258313A1 (en) 2023-12-14
CN117209588A (zh) 2023-12-12
IL317429A (en) 2025-02-01
EP4536695A1 (en) 2025-04-16
KR20250031233A (ko) 2025-03-06
WO2023239290A1 (en) 2023-12-14
US20260021140A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
US12371489B2 (en) Car based immunotherapy
US11596654B2 (en) Human leukocyte antigen restricted gamma delta T cell receptors and methods of use thereof
US20230414661A1 (en) Polypeptide compositions comprising spacers
CN103492406B (zh) 嵌合抗原受体-修饰的t细胞治疗癌症的用途
EP2288700B1 (en) Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
CN111363046A (zh) 靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
JP6580579B2 (ja) Ｔ細胞受容体を発現する細胞を生産する方法および組成物
JP2019506154A (ja) 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法
JP2022065022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
AU2014259675A1 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
JP6777841B2 (ja) 細胞傷害性ｔ細胞の作製方法
US20260021140A1 (en) HBV Surface Antigen Specific T Cell Receptors And Uses Thereof
JP2024514355A (ja) キメラ抗原受容体（ｃａｒ）－ｔ細胞
CN117264043B (zh) 靶向kras g12v突变多肽的t细胞受体及其用途
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
TW202140534A (zh) 個人化醫藥
WO2024153124A1 (zh) 经修饰的原代t细胞及其用途
CN119855899A (zh) 经修饰的靶向乙肝表面抗原的免疫细胞及其医药用途
JP2024514354A (ja) キメラ抗原受容体（ｃａｒ）－ｔ細胞
JP6970417B2 (ja) 細胞傷害性ｔ細胞の作製方法
JP2022132969A (ja) Ｍｒｐ３標的遺伝子改変ｔ細胞
CN118512580A (zh) HBsAg特异性TCR-T细胞与PD-1抑制剂联合在制备治疗HBV感染相关疾病的药物中的用途
JP2024515347A (ja) キメラ抗原受容体（ｃａｒ）－ｔ細胞
WO2024222701A1 (zh) 一种t细胞受体及其用途
HK40024931B (en) Therapeutic agent comprising nucleic acid and tcr modified immune cell and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251203